GlaxoSmithKline
🇬🇧United Kingdom
- Country
- 🇬🇧United Kingdom
- Ownership
- Public
- Established
- 1929-01-01
- Employees
- 70.2K
- Market Cap
- $90B
- Website
- http://www.gsk.com
- Introduction
GSK Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the Commercial Operations, and Research and Development segments. The Commercial Operations segment has three product groups of specialty medicines, vaccines, and general medicines. The company was founded in 1715 and is headquartered in Middlesex, the United Kingdom.
Study to Evaluate Immunogenicity and Safety of GSK Biologicals' Herpes Zoster Subunit (HZ/su) Vaccine at 9 and 10 Years After Vaccine Administration and Assessment of Re-vaccination With 2 Additional Doses at 10 Years After Initial Vaccination, in Healthy Subjects Aged 60 Years of Age(YOA) and Older
Phase 3
Completed
- Conditions
- Herpes Zoster
- Interventions
- Biological: Herpes Zoster Vaccine GSK1437173A
- First Posted Date
- 2016-04-13
- Last Posted Date
- 2024-04-12
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 70
- Registration Number
- NCT02735915
- Locations
- 🇸🇪
GSK Investigational Site, Uppsala, Sweden
A Microdose Study in Healthy Subjects to Describe Intravenous Pharmacokinetics of GSK3191607
- First Posted Date
- 2016-04-13
- Last Posted Date
- 2018-09-13
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 6
- Registration Number
- NCT02737007
- Locations
- 🇬🇧
GSK Investigational Site, London, United Kingdom
A Study Comparing the Closed Triple Therapy, Open Triple Therapy and a Dual Therapy for Effect on Lung Function in Subjects With Chronic Obstructive Pulmonary Disease (COPD)
Phase 3
Withdrawn
- Conditions
- Pulmonary Disease, Chronic Obstructive
- Interventions
- Device: Placebo ELLIPTA inhalerDrug: Albuterol/Salbutamol
- First Posted Date
- 2016-04-08
- Last Posted Date
- 2016-07-22
- Lead Sponsor
- GlaxoSmithKline
- Registration Number
- NCT02731846
- Locations
- 🇩🇪
GSK Investigational Site, Berlin, Germany
Short Term Clinical Study Investigating the Efficacy of an Occluding Dentifrice in Providing Relief From Dentinal Hypersensitivity
Phase 4
Completed
- Conditions
- Dentin Sensitivity
- Interventions
- Other: stannous fluorideOther: sodium monofluorophosphate
- First Posted Date
- 2016-04-08
- Last Posted Date
- 2017-05-17
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 229
- Registration Number
- NCT02731833
- Locations
- 🇨🇦
GSK Investigational Site, Mississauga, Ontario, Canada
Comparative Study of Fluticasone Furoate(FF)/Umeclidinium Bromide (UMEC)/ Vilanterol (VI) Closed Therapy Versus FF/VI Plus UMEC Open Therapy in Subjects With Chronic Obstructive Pulmonary Disease (COPD)
Phase 3
Completed
- Conditions
- Pulmonary Disease, Chronic Obstructive
- Interventions
- First Posted Date
- 2016-04-06
- Last Posted Date
- 2019-07-15
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 1055
- Registration Number
- NCT02729051
- Locations
- 🇪🇸
GSK Investigational Site, Zaragoza, Spain
An Efficacy and Safety Study of Theraflu Night Powder as Oral Solution for Cold and Flu
Phase 3
Withdrawn
- Conditions
- Infections, Respiratory Tract
- Interventions
- First Posted Date
- 2016-04-06
- Last Posted Date
- 2018-03-12
- Lead Sponsor
- GlaxoSmithKline
- Registration Number
- NCT02730364
Pharmacokinetic Study of Gepotidacin in Subjects With Varying Degrees of Renal Impairment and in Subjects With Normal Renal Function
- First Posted Date
- 2016-04-06
- Last Posted Date
- 2020-07-21
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 32
- Registration Number
- NCT02729038
- Locations
- 🇺🇸
GSK Investigational Site, Minneapolis, Minnesota, United States
Crossover Study Comparing Fluticasone Furoate (FF)/Vilanterol (VI) Once Daily Versus Fluticasone Propionate (FP) Twice Daily in Subjects With Asthma and Exercise-Induced Bronchoconstriction (EIB)
Phase 4
Completed
- Conditions
- Asthma
- Interventions
- Drug: Placebo via DISKUS / ACCUHALERDrug: Placebo via ELLIPTA inhaler
- First Posted Date
- 2016-04-06
- Last Posted Date
- 2019-07-16
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 75
- Registration Number
- NCT02730351
- Locations
- 🇨🇦
GSK Investigational Site, Mississauga, Ontario, Canada
A Phase 1, Randomized, Placebo-Controlled, Ascending Cohort, Dose Escalation Study in Normal Healthy Volunteers
- First Posted Date
- 2016-04-04
- Last Posted Date
- 2017-05-08
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 16
- Registration Number
- NCT02727283
- Locations
- 🇦🇺
GSK Investigational Site, Adelaide, South Australia, Australia
Dose Escalation and Expansion Study of GSK3359609 in Participants With Selected Advanced Solid Tumors (INDUCE-1)
Phase 1
Completed
- Conditions
- Neoplasms
- Interventions
- First Posted Date
- 2016-03-31
- Last Posted Date
- 2024-12-27
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 829
- Registration Number
- NCT02723955
- Locations
- 🇪🇸
GSK Investigational Site, Sevilla, Spain
© Copyright 2025. All Rights Reserved by MedPath